Actively Recruiting
Early Longitudinal Imaging in the Parkinson's Progressive Marker Initiative (PPMI) Using (18F)AV-133 (PPMI AV-133 Prodromal Imaging)
Led by Michael J. Fox Foundation for Parkinson's Research · Updated on 2025-12-05
100
Participants Needed
8
Research Sites
213 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The study is a longitudinal, multi-center study to assess progression of \[18F\] AV-133 imaging in Prodromal PD participants. Participants will be followed for up to 24 months. Approximately 100 Prodromal participants will be recruited from up to 10 sites. Participants will be comprehensively assessed at baseline and follow up. Participants will undergo imaging assessments with \[18F\] AV-133 and clinical (motor, neuropsychiatric, cognitive and imaging and biomarker) assessments (conducted under the PPMI Clinical protocol).
CONDITIONS
Official Title
Early Longitudinal Imaging in the Parkinson's Progressive Marker Initiative (PPMI) Using (18F)AV-133 (PPMI AV-133 Prodromal Imaging)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Be a Prodromal Parkinson's disease participant over 18 years old confirmed eligible for the PPMI Clinical Baseline visit
- Able to provide informed consent
- Male or female; females must be non-childbearing or using a highly effective birth control method starting 14 days before until at least 24 hours after the [18F] AV-133 injection
- Non-childbearing females must be postmenopausal for at least 12 months or surgically sterile
- Females of childbearing potential must not be pregnant, breastfeeding, or lactating and must have a negative urine pregnancy test on the day of the PET scan
You will not qualify if you...
- Use of tetrabenazine, methylphenidate, reserpine, or amphetamine derivatives within 1 month before the baseline [18F] AV-133 injection
- Any medical or psychiatric condition or laboratory abnormality that might prevent participation as judged by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 8 locations
1
Institute for Neurodegenerative Disorders
New Haven, Connecticut, United States, 06510
Actively Recruiting
2
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19107
Actively Recruiting
3
Toronto Western Hospital
Toronto, Ontario, Canada, M5T2S8
Not Yet Recruiting
4
Philipps-University of Marburg
Hessen, Germany, 35043
Not Yet Recruiting
5
Tel Aviv Sourasky Medical Center
Tel Aviv, Israel, 64239
Not Yet Recruiting
6
Radboud University
Nijmegen, Gelderland, Netherlands, 6525 GC
Not Yet Recruiting
7
Queen Mary University of London
London, Britain, United Kingdom, EC1M 6BQ
Actively Recruiting
8
Newcastle University
Newcastle upon Tyne, Tyne and Wear, United Kingdom, NE45PL
Actively Recruiting
Research Team
L
Lianne Ramia
CONTACT
J
Jessica Dimos
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here